Our cellular immunotherapy partnerships through NantWorks are developing novel science and medicines including CAR.TNK® technology.
The CAR.TNK technology platform combines NantKwest’s NK-92 cell line with Sorrento’s proprietary G-MAB™ fully human antibody technology and CAR designs further enhancing the anti-cancer potency and tumor targeting of NK-92. Under the terms of this agreement, both companies will jointly select CAR.TNKs to be developed with the ‘lead company’ responsible for advancing the candidates into the clinic. Profit sharing from future sales and potential strategic collaborations with other pharmaceutical partners will be determined by the development stage of the drug candidates.
Immunotherapy NANTiBody JV
NantCell LLC and Sorrento Therapeutics have established a joint venture to focus on the development of a Phase III mAb drug and multiple novel mAbs for valuable drug targets.
Sorrento and NantBioScience, Inc., a subsidiary of NantWorks, have established a joint venture, called NantCancerStemCell, LLC to focus on the development of “first-in-class” small molecules against targets which may address important drivers of cancer growth including cancer stem cells.
Lee’s Pharma has licensed exclusive rights from Sorrento to develop and commercialize the fully human anti-PD-L1 monoclonal antibody (mAb) STI-A1014 for the greater Chinese market, including Mainland China, Hong Kong, Macau, and Taiwan.
Morphotek / Eisai
Concortis Biosystems, Inc., a subsidiary of Sorrento Therapeutics, has entered into a collaboration agreement to generate novel antibody drug conjugates (ADCs) based on a Morphotek antibody linked to chemotherapeutic agents using Concortis’ proprietary ADC Technology.
Sorrento has entered into an exclusive licensing agreement to develop and commercialize multiple prespecified and undisclosed biosimilar or biobetter antibodies from Mabtech Limited, a holding company for premier antibody development and manufacturing companies in China.
The combination of Sorrento’s expertise in immunotherapy and drug development with Mabtech’s experience in antibody development and commercial cGMP manufacturing positions Sorrento as a major player in the biopharmaceutical industry to increase the development and access to effective biosimilars and biobetters.